Just when it seemed like the fiasco at the Coles Group had drawn to a close, the AFR revealed today that the merged retailer just “produced its best first quarter profit figure in five years,” writes Adam Schwab.
Ebit
The sorry saga of Australian Pharmaceutical Industries
One would be hard-pressed to find a better example of how not to run a business than the sorry saga of Australian Pharmaceutical Industries, owner of Priceline, Price Attack and Soul Pattinson.
Can Wesfarmers do a Myer with Coles?
Is the latest word on Coles and Wesfarmers a message from Cassandra (whose prophesy was correct, but was not believed) or Jonah (who got one right, was believed, then got one wrong)? asks retail commentator Rob Lake.
Good prospects for Coles sale, but no private equity fairytale
While leverage and supply chain improvements may make the purchase of Coles at a price of around $17.00 per share an astute deal, it looks very unlikely to be anything like the private equity fairytale that Myer has become.





